Aethlon Medical Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated September 27, 2024, covers the results of Aethlon Medical, Inc.'s 2024 Annual Meeting of Stockholders held on that date. The company is incorporated in Nevada and trades on the Nasdaq Capital Market under the symbol AEMD.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and equity plan amendments rather than financial performance data.
Material Changes and Voting Results
At the Annual Meeting, approximately 36.14% of the 13,937,327 outstanding shares were represented. Stockholders approved the following key proposals:
- Equity Plan Amendment: Approved an amendment to the 2020 Equity Incentive Plan to increase the number of authorized shares by 3,000,000. This amendment became effective immediately upon approval.
- Director Elections: Elected five directors (Edward G. Broenniman, James B. Frakes, Nicolas Gikakis, Angela Rossetti, and Chetan S. Shah, MD). Each received significant support, with "Against" votes ranging from approximately 157,000 to 173,000.
- Accounting Firm Ratification: Ratified the appointment of Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2025.
- Executive Compensation: Approved, on a non-binding advisory basis, the compensation of named executive officers.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors. The document references the Definitive Proxy Statement filed on August 15, 2024, for additional details on the equity plan terms and executive compensation.
Investor Verification Checklist
- Verify the full text of the Amended 2020 Equity Incentive Plan (Exhibit 10.1) to understand vesting schedules and dilution implications of the 3,000,000 share increase.
- Review the August 15, 2024 Proxy Statement for detailed executive compensation data referenced in Proposal No. 4.
- Monitor the company's upcoming financial reports for the fiscal year ending March 31, 2025, as the new accounting firm has been ratified.
- Confirm the status of the interim leadership, noting James B. Frakes signed the report as Interim CEO and CFO.